Literature DB >> 4031927

Myasthenia gravis: long-term prognostic value of thymus lactate dehydrogenase isoenzyme pattern of hyperplastic thymus and thymoma.

I Szathmáry, L Selmeci, E Pósch, A Szobor, J Molnár.   

Abstract

Lactate dehydrogenase (LDH) isoenzyme pattern and the percent of H-subunit content were determined in the thymus of 62 patients (55 with hyperplasia, 7 with tumours) after thymectomy. An increase in LDH1 relative activity indicates that in the thymus of patients with myasthenia gravis the ratio of mature differentiated thymocytes was higher than in the thymus of control subjects. LDH isoenzyme profiles of thymus tumours were similar to those described in other neoplasms, except that thymomas with apparent predominance of epithelial cells and with minimal lymphocytic reaction exhibited a marked elevation only in LDH2 relative activity, presumably associated with the specific (secretory) function of epithelial cells. The elevation of H-subunit content, a parameter characteristic of both thymic components (lymphoid and epithelial), correlated closely with a poor clinical condition in patients several years after surgery.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031927      PMCID: PMC1028446          DOI: 10.1136/jnnp.48.8.757

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  23 in total

1.  An improved technique of agar-gel electrophoresis on microscope slides.

Authors:  R J WIEME
Journal:  Clin Chim Acta       Date:  1959-05       Impact factor: 3.786

2.  Lactate dehydrogenase isoenzyme pattern as a measure of cellular differentiation in lymphocytic cells.

Authors:  J Plum; S Ringoir
Journal:  J Reticuloendothel Soc       Date:  1977-04

3.  Acid esterase in human lymphoid cells and leukaemic blasts: a marker for T lymphocytes.

Authors:  J Kulenkampff; G Janossy; M F Greaves
Journal:  Br J Haematol       Date:  1977-06       Impact factor: 6.998

Review 4.  Hormonal influences on the reticuloendothelial system: current status of the role of thymosin in the regulation and modulation of immunity.

Authors:  A L Goldstein; G B Thurman; T L Low; J L Rossio; G E Trivers
Journal:  J Reticuloendothel Soc       Date:  1978-04

Review 5.  Resurgence of fetal isozymes in cancer: study of aldolase, pyruvate kinase, lactic dehydrogenase, and beta-hexosaminidase.

Authors:  F Schapira
Journal:  Isozymes Curr Top Biol Med Res       Date:  1981

6.  Thymic myogenesis, T-lymphocytes and the pathogenesis of myasthenia gravis.

Authors:  H Wekerle; R Hohlfeld; U P Ketelsen; J R Kalden; I Kalies
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

7.  Identification of human thymic epithelial cells with antibodies to thymosin alpha 1 in myasthenia gravis.

Authors:  M C Dalakas; W K Engel; J E McClure; A L Goldstein; V Askanas
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

8.  Thymic abnormalities: antigen or antibody? Response to thymectomy in myasthenia gravis.

Authors:  A S Penn; A Jaretzki; M Wolff; H W Chang; V Tennyson
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

9.  Myasthenia gravis: a quantitative evaluation system. Disability status scale (DSS) applied for myasthenia gravis.

Authors:  A Szobor
Journal:  Eur Neurol       Date:  1976       Impact factor: 1.710

10.  [Ultrastructure of the thymus and neuromuscular junction in myasthenic and non-myasthenic patients].

Authors:  S Szekamova; G Répássy; K Lapis; A Szobor; I Szathmáry
Journal:  Morphol Igazsagugyi Orv Sz       Date:  1978-04
View more
  1 in total

1.  Potential Prognostic Value of Preoperative Leukocyte Count, Lactate Dehydrogenase and C-Reactive Protein in Thymic Epithelial Tumors.

Authors:  Daniel Valdivia; Danjouma Cheufou; Benjamin Fels; Stephan Puhlvers; Khaled Mardanzai; Mohamed Zaatar; Gerhard Weinreich; Christian Taube; Dirk Theegarten; Martin Stuschke; Martin Schuler; Georgios Stamatis; Balazs Hegedus; Clemens Aigner
Journal:  Pathol Oncol Res       Date:  2021-04-21       Impact factor: 3.201

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.